Quick Answer
Lipocine Inc. reported Total Revenue of $1.98 million for fiscal year 2025.
Lipocine Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.98M -82.3% |
$11.20M +492.8% |
-$2.85M -670.2% |
$500.0K -96.9% |
$16.14M | $0.00 -100.0% |
| Revenue (ASC 606) | — | — | — | $500.0K -96.9% |
$16.14M | — |
| Net Income | -$9.63M -115371.9% |
$8.4K +100.1% |
-$16.35M -52.0% |
-$10.76M -1595.9% |
-$634.4K +97.0% |
-$20.96M -61.2% |
| Diluted EPS | -$1.69 | — | -$3.14 -46.0% |
-$2.15 -21400.0% |
-$0.01 +97.4% |
-$0.38 +24.0% |
| Total Assets | $17.01M -24.5% |
$22.51M -2.1% |
$23.00M -38.7% |
$37.54M -28.5% |
$52.48M +107.0% |
$25.35M +29.0% |
| Cash and Equivalents | $5.21M -16.1% |
$6.21M +30.1% |
$4.77M +51.6% |
$3.15M +6.7% |
$2.95M -84.6% |
$19.22M +97.5% |
| Long-Term Debt | — | — | — | — | — | $2.26M -40.8% |
| Stockholders Equity | $14.48M -31.1% |
$21.00M +3.1% |
$20.37M -42.8% |
$35.63M -21.8% |
$45.57M +197.0% |
$15.34M +144.0% |
| R&D Expense | $8.58M +16.8% |
$7.35M -27.7% |
$10.18M +18.9% |
$8.56M +11.6% |
$7.67M -21.4% |
$9.75M +30.5% |
| Operating Income | -$10.37M -797.9% |
-$1.16M +93.6% |
-$17.93M -48.0% |
-$12.12M -485.3% |
$3.15M +117.5% |
-$18.00M -39.5% |
| Shares Outstanding | 6.16M +15.2% |
5.35M +0.6% |
5.32M +1.5% |
5.23M -94.1% |
88.29M +26.1% |
70.04M +86.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $114.6K | — | -81.6% |
| Revenue (ASC 606) | March 31, 2023 | $55.0K | — | -89.0% |
| Net Income | September 30, 2025 | -$3.19M | -43.6% | -44.5% |
| Diluted EPS | September 30, 2025 | -$0.59 | -34.1% | -43.9% |
| Total Assets | September 30, 2025 | $16.07M | -22.3% | -13.5% |
| Cash and Equivalents | September 30, 2025 | $3.90M | +4.2% | -35.5% |
| Long-Term Debt | March 31, 2021 | $1.44M | -69.2% | -36.1% |
| Stockholders Equity | September 30, 2025 | $14.14M | -26.0% | -17.4% |
| R&D Expense | September 30, 2025 | $2.71M | +70.8% | +26.7% |
| Operating Income | September 30, 2025 | -$3.36M | -27.8% | -39.8% |
| Shares Outstanding | September 30, 2025 | 5.42M | +1.4% | +0.9% |
- Lipocine Inc. reported Total Revenue of $1.98 million for fiscal year 2025.
- Lipocine Inc. showed a decrease of -82.3% in Total Revenue compared to the prior fiscal year.
- Lipocine Inc. reported Revenue (ASC 606) of $500.0 thousand for fiscal year 2022.
- Lipocine Inc. showed a decrease of -96.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Lipocine Inc. reported Net Income of -$9.63 million for fiscal year 2025.
- Lipocine Inc. showed a decrease of -115371.9% in Net Income compared to the prior fiscal year.
- Lipocine Inc. reported Diluted EPS of $1.69 per share (loss) for fiscal year 2025.
- Lipocine Inc. showed an increase of +46.2% in Diluted EPS compared to the prior fiscal year.
- Lipocine Inc. reported Total Assets of $17.01 million for fiscal year 2025.
- Lipocine Inc. showed a decrease of -24.5% in Total Assets compared to the prior fiscal year.
- Lipocine Inc. reported Cash and Equivalents of $5.21 million for fiscal year 2025.
- Lipocine Inc. showed a decrease of -16.1% in Cash and Equivalents compared to the prior fiscal year.
- Lipocine Inc. reported Long-Term Debt of $2.26 million for fiscal year 2020.
- Lipocine Inc. showed a decrease of -40.8% in Long-Term Debt compared to the prior fiscal year.
- Lipocine Inc. reported Stockholders Equity of $14.48 million for fiscal year 2025.
- Lipocine Inc. showed a decrease of -31.1% in Stockholders Equity compared to the prior fiscal year.
- Lipocine Inc. reported R&D Expense of $8.58 million for fiscal year 2025.
- Lipocine Inc. showed an increase of +16.8% in R&D Expense compared to the prior fiscal year.
- Lipocine Inc. reported Operating Income of -$10.37 million for fiscal year 2025.
- Lipocine Inc. showed a decrease of -797.9% in Operating Income compared to the prior fiscal year.
- Lipocine Inc. reported Shares Outstanding of 6.16 million shares for fiscal year 2025.
- Lipocine Inc. showed an increase of +15.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: